taking semaglutide and tirzepatide vs. Semaglutide: Which is Best for Weight Loss? Tirzepatide vs Semaglutide: What's the

Highlights of 2024: The year the obesity market took shape The market for anti-obesity medications (AOMs) reached a major milestone in 2024 with global spend exceeding $30Bn for the first time, an over ten-fold increase since 2020

The cost of tirzepatide represents a significant consideration for patients and healthcare systems, as no generic alternative currently exists to provide price competition

Tirzepatide also demonstrated a generally favorable safety profile with most side effects gastrointestinal in nature

80Alberta recognizes obesity as a chronic disease: now its time for action [news release]

The obesity-breast cancer link: a multidisciplinary perspective

From a safety perspective, adverse effects such as pancreatitis and gallbladder disease can occur at any dose, and the risk profile at microdoses is undefined